ArticleDiscover oncology2025
LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approach.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the role of MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) in endometrial cancer, focusing on its expression levels, prognostic significance, and functional impact on tumor biology. RT-qPCR analysis revealed significant upregulation of MALAT1 in endometrial cancer tissues compared to adjacent normal tissues (p < 0.001), with higher expression observed in advanced tumor stages and a correlation with lymphovascular invasion (p < 0.01). Kaplan-Meier survival analysis demonstrated that high MALAT1 expression was associated with shorter overall survival (OS) and progression-free survival (PFS) (log-rank test, p < 0.05). Functional assays indicated that MALAT1 knockdown in Ishikawa and HEC-1A cell lines resulted in decreased cell proliferation, increased apoptosis, and impaired angiogenesis (p < 0.01). Mechanistically, MALAT1 was found to act as a competing endogenous RNA (ceRNA), sponging tumor-suppressive microRNAs such as miR-200c and miR-145, thereby regulating key oncogenic pathways. Additionally, a strong positive correlation was identified between MALAT1 expression and clinical features, including VEGFA and ZEB1. Therapeutically, MALAT1 silencing using antisense oligonucleotides in a xenograft mouse model significantly reduced tumor growth and microvessel density (p < 0.01). These findings suggest that MALAT1 is a promising biomarker and therapeutic target in endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.